As the biotechnology sector continues to recover from a period of slow growth, the new year is finding the industry facing potential fallout if sequestration goes forward. With early stage venture funding dried up and IPOs rare, younger, smaller companies are eyeing alternative sources of investment. They are also being encouraged to think about how they will commercialize their products, even before clinical trials get started. Potential partners are demanding more from the companies they back.
Those were some of the issues that punctuated the BIO CEO conference in New York this week. Now that the conference has wrapped up, here are some of the thought leaders, industry insiders and reporters from the biotech sector worth following on Twitter.
Laura Strong (@scientre) runs a private, clinical stage biotech company developing cancer drugs.
Marie Powers (@mariempowers) a staff writer at BioWorld Today.